Talon Therapeutics Inc news

   Watch this stock
Showing stories 1 - 8 of about 8   

Articles published

TLON 0.156
price chart
Daiichi Sankyo Names New Executive Appointment
Also responsible for business development at Spectrum, he was integral to the successful acquisition and integration of Talon Therapeutics into the company. Prior to Spectrum, Keller spent 21 years at Amgen rising through the organization as a ...
Related articles »  
Daiichi Sankyo Names US Commercial Ops President
Also responsible for business development at Spectrum, he was integral to the successful acquisition and integration of Talon Therapeutics into the company. Prior to Spectrum, Mr. Keller spent 21 years at Amgen rising through the organization as a ...
Ken Keller Named President, US Commercial, Daiichi Sankyo, Inc.
Also responsible for business development at Spectrum, he was integral to the successful acquisition and integration of Talon Therapeutics into the company. Prior to Spectrum, Mr. Keller spent 21 years at Amgen rising through the organization as a ...
Related articles »  
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline ...
However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.).
Related articles »  
Tekmira and Theralase Leaders in Innovative Drug Therapies
The Burnaby, BC-based company has reached commercialization by licensing Marqibo, an FDA-approved liposomal formulation of vincristine for the treatment of certain acute lymphoblastic leukemia (ALL) patients, to Talon Therapeutics, which was ...
Related articles »